TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01711723
Drug: Darapladib 160 mg
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
Study: NCT01827618
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01992198
Drug: cefoperazone + metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h
Study: NCT01992198
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01992198
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 \>95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h
Study: NCT02999126
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
Study: NCT03307759
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab
Study: NCT00004468
Drug: calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03271021
Drug: Vehicle Foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Foam
Study: NCT00038168
Drug: Estramustine
Normalized name: Estramustine
DrugBank: Estramustine (DB01196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose
Study: NCT00038168
Drug: Taxol
Normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous dose
Study: NCT02175004
Drug: Inotersen
Normalized name: INOTERSEN
DrugBank: Inotersen (DB14713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotersen SC
Study: NCT00871780
Drug: BG00002 (natalizumab)
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00526617
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT00526617
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsules
Study: NCT03363906
Drug: Dulaglutide (Reference)
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered SC
Study: NCT01051011
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
Study: NCT01051011
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: as prescribed
Study: NCT01051011
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg sc weekly, 24 (-52) weeks
Study: NCT03363906
Drug: Dulaglutide (Test)
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered SC
Study: NCT02059239
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
Study: NCT02059239
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/m2 on Day -6
Study: NCT02059239
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 on days -5 to -2
Study: NCT02059239
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140mg/m2 on Day -1
Study: NCT02059239
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 on days -5 to -2
Study: NCT02059239
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
Study: NCT02059239
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
Study: NCT04487990
Drug: unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of unfractioned heparin to CVVHD system already running under citrate regional anticoagulation.
Study: NCT01051011
Drug: taspoglutide
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
Study: NCT03608020
Drug: BMX-001
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese butoxyethyl pyridyl porphyrin
Study: NCT01155245
Drug: Forteo
Normalized name: Forteo
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Forteo pen
Study: NCT00048854
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
Study: NCT01807767
Drug: Everolimus, Myfortic and Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID
Study: NCT01807767
Drug: Myfortic and Tacrolimus
Normalized name: Myfortic
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
Study: NCT01607554
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician
Study: NCT01419457
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1200 mg BID for Day 1 + 800 mg BID for Day 2-5
Study: NCT01419457
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 800 mg BID for Day 1 + 400 mg BID for Day 2-3
Study: NCT01419457
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 800 mg Single Dose
Study: NCT03956823
Drug: telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan group: telmisartan 80 mg once a day
Study: NCT03956823
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine group: amlodipine 5 mg once a day
Study: NCT00787878
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGA previously treated with Norditropin®
Study: NCT01795664
Drug: Salmeterol xinafoate and Fluticasone propionate HFA pMDI
Normalized name: salmeterol
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)
Study: NCT01795664
Drug: Seretide Evohaler
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)
Study: NCT00193453
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 30min IV, Day 1 \& 8
Study: NCT00193453
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg/m2, 30min IV, day 1 \& 8
Study: NCT00193453
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
Study: NCT04647643
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel to treat peripheral arterial disease
Study: NCT02652871
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.
Study: NCT02652871
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days.
Study: NCT01186861
Drug: OSI-906
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered with food and with up to 200 mL of water
Study: NCT03261999
Drug: Leuprolide Mesylate
Normalized name: Leuprolide Mesylate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 25mg Leuprolide Mesylate
Study: NCT00919880
Drug: carboplatin+ paclitaxel
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 2mg/mL\*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study: NCT00919880
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
Study: NCT00472420
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 iv every 3 weeks
Study: NCT00686972
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
Study: NCT04528927
Drug: HCQ
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
Study: NCT04494646
Drug: Bardoxolone Methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of bardoxolone methyl (20mg)
Study: NCT01927029
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
Study: NCT01186861
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Study: NCT02219256
Drug: TAK-079
Normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 solution
Study: NCT02219256
Drug: Placebo to TAK-079
Normalized name: Anti-Cd38 monoclonal antibody TAK-079
DrugBank: Mezagitamab (DB16370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to TAK-079 solution
Study: NCT00747929
Drug: S-2367 Placebo
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
Study: NCT00747929
Drug: S-2367 800 mg
Normalized name: TPG-S
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
Study: NCT00747929
Drug: S-2367 1600 mg
Normalized name: TPG-S
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
Study: NCT03896230
Drug: Ketamine Injectable Product
Normalized name: ketamine Injectable Product
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three different doses of ketamine will be administered.
Study: NCT02613897
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
Study: NCT02613897
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
Study: NCT01405586
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
Study: NCT00117754
Drug: Terbinafine hydrochloride
Normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01405586
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
Study: NCT01405586
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 day 1 every 3 weeks for 6 cycles
Study: NCT00257062
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01040780
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg three times daily (375 mg per day) by mouth
Study: NCT01040780
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg every 24 hours by mouth
Study: NCT00654940
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral, 75mg or 150mg capsules, BID
Study: NCT00802737
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
Study: NCT01485055
Drug: Infliximab and Basiliximab
Normalized name: Basiliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times.
Study: NCT00241605
Drug: rosiglitazone/metformin
Normalized name: rosiglitazone/metformin HCl 1 mg-500 mg ORAL TABLET
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01778023
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
Study: NCT02408419
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine is injected proximally to anesthetize the obturator nerve
Study: NCT02408419
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline is injected as a placebo
Study: NCT01879293
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01098097
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
Study: NCT01657513
Drug: subjects will receive either infliximab, adalimumab or etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines
Study: NCT01411215
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25mg biweekly or 50mg per week, subcutaneous injection
Study: NCT01884987
Drug: GM1
Normalized name: pGM169/GL67A
DrugBank: pGM169/GL67A (DB17917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
Study: NCT00035958
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00035958
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04463017
Drug: HU6
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study: NCT00075647
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01710462
Drug: Pantoprazole + Domperidone
Normalized name: Domperidone
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00838071
Drug: Specific intravenous anti-hepatitis B immunoglobulin
Normalized name: hepatitis B immunoglobulin
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly doses of 5000 IU administered intravenously during 6 consecutive months
Study: NCT01532726
Drug: ESL
Normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ESL 400/800/1200 mg tablets once daily
Study: NCT00174512
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01600573
Drug: pazopanib in combination with weekly topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary.
Study: NCT00437463
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
Study: NCT01924533
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
Study: NCT01924533
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.